参考文献
[1] 周春霞，孙婧，徐凤琴，等.流感病毒性肺炎治疗研究进展[J].中华医院感染学杂志，2020,30(2):302-307.
[2] 林丽丽，冯璐，黄克，等.儿童病毒性肺炎分期防治的中医药研究进展及策略探析[J].南京中医药大学学报，2021,37(6):949-957.
[3] 周旭，李书晴，王艳萍，等.中医药干预病毒性肺炎随机对照试验的系统评价[J].中华中医药杂志，2021,36(2):1094-1097.
[4] 胡亚美，江载芳.诸福棠实用儿科学[M].北京：人民卫生出版社，2002 :1197.
[5] 王永炎，严世芸.实用中医内科学[M].上海：上海科学技术出版社，2009:39-42.
[6] 郑筱萸.中药新药临床研究指导原则：试行[S].北京：中国医药科技出版社，2002:88-90.
[7] 国家中医药管理局.中医病证诊断疗效标准[M].南京：南京大学出版社，1994:21-22.
[8] 许异川，胡静.论温病学“寓攻于补”思想在病毒性肺炎治疗中的运用[J].中国中医基础医学杂志，2020,26(9):1257-1260.
[9] 沈慧琴，王红艳.桂枝加厚朴杏子汤加味治疗慢阻肺急性加重期的临床效果观察[J].中医学报，2020,14(2):151-153.
[10] 姚维佳，周天梅.桂枝加厚朴杏子汤治疗神经科疑难杂症经验[J].浙江中医药大学学报，2021,45(1):56-59.
[11] 钱深思，刘美怡，容蓉，等.柴胡桂枝汤治疗呼吸道疾病的现代研究进展[J].时珍国医国药，2021,32(5):1210-1213.
[12] 何琛璐，王雪君，刘润武，等.桂枝加厚朴杏子汤联合孟鲁司特钠对咳嗽变异性哮喘患者的临床疗效[J].中成药，2021,43(10):2690-2694.
[13] 樊启猛，潘雪，贺玉婷，等.中药及其复方对病毒性肺炎的免疫调节作用研究进展[J].中草药，2020,51(8):2065-2074.
[14] 张间霞，庄健海，吕微风，等.成年病毒性肺炎患者T淋巴细胞亚群的水平变化及临床意义[J].检验医学与临床，2020,17(24):3601-3603.
[15] PULJIZ I,MARKOTIC A,CVETKO KRAJINOVIC L,et al.Mycoplasma pneumoniae in adult community-acquired pneumonia increases matrix metalloproteinase-9 serum level and induces its gene expression in peripheral blood mononuclear cells[J].Med Sci Monit.2012,18(8):C500-505.
参考文献
[1] Zhang Q H, Wu C F, Duan L, et al. Protective effects of ginsenoside Rg(3) against cyclophosphamide-induced DNA damage and cell apoptosis in mice [J]. Arch Toxicol, 2008, 82(2):117-123.
[2] 张均田.人参研究的最新进展[J].江苏大学学报（医学版）,2009,19(3):185-191.
[3] Zhou P, Xie W, He S, et al. Ginsenoside Rb1 as an Anti-Diabetic Agent and Its Underlying Mechanism Analysis[J]. Cells, 2019,8(3).
[4] 季云,陈永昌,马锦洪,等.人参皂苷Rb-2对肠道病毒71型的体外抑制效应[J].江苏大学学报（医学版）,2016, 26(3):215-218.
[5] 王晓丽,金跃,刘鹭,等.人参皂苷Rg1改善小鼠肢体缺血后血管新生[J].江苏大学学报（医学版）,2018, 28(2):126-128, 134.
[6] Kang Z, Zhonga Y, Wu T, et al. Ginsenoside from ginseng: a promising treatment for inflammatory bowel disease [J]. Pharmacol Rep, 2021,73(3):700-711.
[7] Shin B K, Kwon S W, Park J H. Chemical diversity of ginseng saponins from Panax ginseng [J]. J Ginseng Res, 2015, 39(4):287-298.
[8] He B, Chen D, Zhang X, et al. Oxidative Stress and Ginsenosides: An Update on the Molecular Mechanisms[J]. Oxid Med Cell Longev, 2022,2022:9299574.
[9] Fan W, Huang Y, Zheng H, et al. Ginsenosides for the treatment of metabolic syndrome and cardiovascular diseases: Pharmacology and mechanisms [J]. Biomed Pharmacother, 2020, 132: 110915.
[10] 冯瑶,陈新怡,宋厚盼,等.基于生物信息学的十二指肠腺瘤核心致病基因及其靶向治疗中药活性成分筛选[J].江苏大学学报（医学版）, 2021, 31(2): 158-165.
[11] Wu HC, Hu QR, Luo T, et al. The immunomodulatory effects of ginsenoside derivative rh2-o on splenic lymphocytes in h22 tumor-bearing mice is partially mediated by tlr4 [J]. Int Immunopharmacol, 2021, 101: 108316.
[12] Hong T, Kim MY, Da Ly D, et al. Ca2+ activated mitochondrial biogenesis and functions improve stem cell fate in rg3-treated human mesenchymal stem cells [J]. Stem Cell Res Ther, 2020, 11(1): 467.
[13] Liu X, Zhang Z, Liu J, et al. Ginsenoside Rg3 improves cyclophosphamide-induced immunocompetence in Balb/c mice[J]. Int Immunopharmacol, 2019,72:98-111.
[14] 冉瑞图, 孙嘉政, 张晶, 等. 人参皂苷rg1对衰老大鼠胸腺结构与功能的影响 [J]. 中国老年学杂志, 2015, (10): 2593-2596.
[15] Zheng ZY, Yu XL, Dai TY, et al. Panaxdiol saponins component promotes hematopoiesis and modulates t lymphocyte dysregulation in aplastic anemia model mice [J]. Chin J Integr Med, 2019, 25(12): 902-910.
[16] Cao H, Wei W, Xu R, et al. Ginsenoside rg1 can restore hematopoietic function by inhibiting bax translocation-mediated mitochondrial apoptosis in aplastic anemia [J]. Sci Rep, 2021, 11(1): 12742.
[17] Zhang H, Zhang L, Yang C, et al. Prevention effect of protopanaxadiol-type saponins saponins and protopanaxatriol-yype saponins on myelosuppression mice induced by cyclophosphamide [J]. Front Pharmacol, 2022, 13(845034).
[18] 吴日辉, 茹琴, 李超英. 人参皂苷rg3不同构型对肝癌小鼠抗氧化能力的比较研究 [J]. 医学信息, 2014, (22): 155.
[19] Wang M, Yan SJ, Zhang HT, et al. Ginsenoside rh2 enhances the antitumor immunological response of a melanoma mice model [J]. Oncol Lett, 2017, 13(2): 681-685.
[20] Wang L, Zhang Y, Chen J, et al. Immunosuppressive effects of ginsenoside-rd on skin allograft rejection in rats [J]. J Surg Res, 2012, 176(1): 267-274.
[21] Kleinewietfeld M, Hafler DA. The plasticity of human treg and th17 cells and its role in autoimmunity [J]. Semin Immunol, 2013, 25(4): 305-312.
[22] Park YJ, Cho M, Choi G, et al. A critical regulation of th17 cell responses and autoimmune neuro-inflammation by ginsenoside rg3 [J]. Biomolecules, 2020, 10(1): 122.
[23] Zhang M, Hu S, Tao J, et al. Ginsenoside compound-k inhibits the activity of b cells through inducing igd-b cell receptor endocytosis in mice with collagen-induced arthritis [J]. Inflammopharmacology, 2019, 27(4): 845-856.
[24] Chen J, Wang Q, Wu H, et al. The ginsenoside metabolite compound k exerts its anti-inflammatory activity by downregulating memory b cell in adjuvant-induced arthritis [J]. Pharm Biol, 2016, 54(7): 1280-1128.
[25] 余昕. 四种人参皂苷单体对系统性红斑狼疮体液免疫的调节作用 [M]. 第二军医大学. 2017.
[26] Wu K, Lin K, Li X, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment [J]. Front Immunol, 2020, 11: 1731.
[27] Kang S, Park SJ, Lee AY, et al. Ginsenoside rg(3) promotes inflammation resolution through m2 macrophage polarization [J]. J Ginseng Res, 2018, 42(1): 68-74.
[28] Li H, Huang N, Zhu W, et al. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside rh2 [J]. BMC Cancer, 2018, 18(1): 579.
[29] Liu KK, Wang QT, Yang SM, et al. Ginsenoside compound k suppresses the abnormal activation of t lymphocytes in mice with collagen-induced arthritis [J]. Acta Pharmacol Sin, 2014, 35(5): 599-612.
[30] Wang R, Zhang M, Hu S, et al. Ginsenoside metabolite compound-k regulates macrophage function through inhibition of β-arrestin2 [J]. Biomed Pharmacother, 2019, 115: 108909.
[31] Kim SJ, Lee J, Choi WS, et al. Ginsenoside f1 attenuates eosinophilic inflammation in chronic rhinosinusitis by promoting nk cell function [J]. J Ginseng Res, 2021, 45(6): 695-705.
[32] Kwon HJ, Lee H, Choi GE, et al. Ginsenoside f1 promotes cytotoxic activity of nk cells via insulin-llike growth factor-1-dependent mechanism [J]. Front Immunol, 2018, 9: 2785.
[33] Lee Y, Park A, Park YJ, et al. Ginsenoside 20(r)-rg3 enhances natural killer cell activity by increasing activating receptor expression through the mapk/erk signaling pathway [J]. Int Immunopharmacol, 2022, 107: 108618.
[34] 王毅, 郝钰, 邱全瑛, 等. 人参皂苷Rg1与Rh1对树突状细胞表达HLA-DR、CD25、CD44、CD54、CD11c及E-selectin的影响[J]. 中国免疫学杂志, 2007(01):46-48.
[35] Chen J, Wu H, Wang Q, et al. Ginsenoside metabolite compound K suppresses T-cell priming via modulation of dendritic cell trafficking and costimulatory signals, resulting in alleviation of collagen-induced arthritis[J]. J PharmacolExpTher, 2015,353(1):71-79.
[36] 雒宏, 陈雁飞, 钱军. 人参皂苷对胶原诱导类风湿关节炎小鼠脾脏树突状细胞亚群的影响[J]. 临床和实验医学杂志, 2021,20(10):1021-1025.
[37] Son K J, Choi K R, Lee S J, et al. Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy[J]. Immune Netw, 2016,16(1):75-84.
[38] Long J, Liu X K, Kang Z P, et al. Ginsenoside Rg1 ameliorated experimental colitis by regulating the balance of M1/M2 macrophage polarization and the homeostasis of intestinal flora [J]. Eur J Pharmacol, 2022, 917:174742.
[39] Lee Y J, Son Y M, Gu M J, et al. Ginsenoside fractions regulate the action of monocytes and their differentiation into dendritic cells[J]. J Ginseng Res, 2015,39(1):29-37.
[40] 尤艳利, 凌昌全, 封颖璐,等. 人参皂苷联合泼尼松治疗系统性红斑狼疮的随机双盲对照研究[J]. 中国中西医结合杂志, 2009,29(09):776-779.
[41] Park H Y, Lee S H, Lee K S, et al. Ginsenoside Rg1 and 20(S)-Rg3 induce IgA production by mouse B cells [J]. Immune Netw, 2015, 15(6):331-336.
[42] Yu X, Zhang N, Lin W, et al. Regulatory effects of four ginsenoside monomers in humoral immunity of systemic lupus erythematosus [J]. ExpTher Med, 2018, 15 (2):2097-2103.
参考文献
[1] 王新燕,宫凯,于明涛.观察沙美特罗替卡松粉吸入剂用于支气管哮喘治疗的临床有效率[J].当代医学,2020,26(35):15-17.
[2] 常立生.沙美特罗替卡松粉吸入剂对支气管哮喘的治疗效果分析[J].中国现代药物应用,2021,15(7):146-148.
[3] 杨娜.扎鲁司特联合沙美特罗替卡松粉吸入剂在老年支气管哮喘缓解期患者中的应用价值[J].河南医学研究,2019,28(21):3924-3926.
[4] 中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675-697.
[5] 赵仁海,葛云蕊,董晓明.布地奈德联合常规抗哮喘治疗对儿童支气管哮喘症状改善及对T淋巴细胞亚群的影响[J].吉林医学,2021,42(11):2688-2690.
[6] 任大鹏,闫永彬,李君,等.搜风愈喘方辅助治疗小儿支气管哮喘急性发作的效果[J].临床医学,2021,41(10):118-120.
[7] 姜萌.中药穴位敷贴专项护理小儿支气管哮喘疗效及对免疫功能的影响[J].新中医,2020,52(10):150-152.
[8] 王德军.哮喘控制测试问卷在哮喘中的应用效果[J].中国现代医生,2016,54(14):88-90.
[9] 张蔚,文昌菊.多索茶碱联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的疗效[J].慢性病学杂志,2020,21(9):1441-1443.
[10] 陆玮芬,吴娟,陈春荣.布地奈德吸入联合孟鲁司特钠口服对支气管哮喘患儿气道功能重塑和免疫球蛋白水平的影响[J].中国妇幼保健,2022,37(2):255-258.
[11] 谢树宏.维生素A联合沙美特罗替卡松粉吸入剂在儿童支气管哮喘治疗中的临床价值分析[J].中国医学创新,2021,18(2):48-51.
[12] 钟明含.舒利迭联合扎鲁司特治疗儿童支气管哮喘的疗效观察[J].中国冶金工业医学杂志,2020,37(2):204.
[13] 唐绘卓.孟鲁司特辅助治疗儿童支气管哮喘的效果及对血清炎性因子、T淋巴细胞亚群指标的影响[J].现代医用影像学,2019,28(9):2128-2130.
[14] 江瑞娟.不同剂量沙丁胺醇雾化治疗儿童支气管哮喘急性发作的临床研究[J].现代药物与临床,2021,36(2):345-349.
[15] 柳洲.扎鲁司特联合沙美特罗替卡松粉吸入剂治疗支气管哮喘患儿的疗效[J].中国合理用药探索,2019,16(5):108-110.
[16] 何雯,毕良学,王宁玲.支气管哮喘患儿白介素、TNF-α与肺功能及免疫功能的关系研究[J].临床输血与检验,2020,22(6):638-642.
[17] 刘明伟,何丽仪.沙美特罗替卡松粉吸入剂联合舒利迭用药管理仪治疗儿童支气管哮喘的效果观察[J].中国现代药物应用,2020,14(13):170-172.
[18] 陈晓倩,钟韩荣,何丽仪.分析沙美特罗替卡松联合脱敏疗法治疗儿童支气管哮喘的临床疗效[J].中国现代药物应用,2020,14(13):173-175.
[19] 牛磊,汪隽瑛,蒋瑾瑾.白三烯诱导人呼吸道上皮细胞氧化应激及γ-谷氨酰半胱氨酸合成酶的作用研究[J].临床儿科杂志,2012,30(1):66-69.
[20] 王涛,马义磊,周进.沙美特罗替卡松粉吸入剂联合噻托溴铵粉吸入剂对哮喘患者炎症因子及免疫功能的影响[J].浙江中西医结合杂志,2021,31(2):125-128.
[21] 乔进,朱立成,赵彦.三拗片与沙美特罗替卡松粉吸入治疗联用对咳嗽变异性哮喘患者的疗效及其对免疫功能与肺功能的影响[J].抗感染药学,2021,18(1):127-131.